The Swiss medication giant reported three meetings with federal officials in the past week, two of which were with Health Canada and foreign affairs officials to discuss “policies related to the importation of pharmaceuticals from Canada to the United States.” On Monday, Trump signed a directive to lower drug prices in the U.S. Then on Tuesday, the White House said it had launched a national security investigation to assess the need for tariffs on medications,  one of the country’s biggest imports.

In Trump’s Monday directive, he referenced plans to allow states to import less-expensive drugs from Canada. Canadians pay, on average, three times less for name-brand medications than U.S. residents because of Canada’s price control rules for drug manufacturers. During his first term, Trump opened the door to allow states to make deals with pharmaceutical companies to buy less expensive drugs from Canada. U.S. lawmakers across the political spectrum — from Bernie Sanders to Ron DeSantis — supported the idea. Florida was the first state to apply to the U.S. Food and Drug Administration (FDA) to implement a plan. The state’s importation proposal was approved by Joe Biden’s FDA just over a year ago. Other states, including Colorado, New York and Texas, also have applications pending.